AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16432810 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 246
Study 16432810 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 246
Study 15606395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 12 weeks) + Infliximab (5 mg/kg at weeks 6, 8, and 12)
Number of subjects: 24
Study 15606395 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Infliximab (5 mg/kg at weeks 6, 8, and 12)
Number of subjects: 24
Study 15606395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 12 weeks)
Number of subjects: 24
Study 11678745 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated information system
Number of subjects: 40
Study 11678745 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 40
Study 11678745 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for information system
Number of subjects: 40
Study 9401833 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 28
Study 9401833 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER 5 mg
Number of subjects: 28
Study 9401833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 28
Study 7505563 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride, 5 mg for 24 months
Number of subjects: 298
Study 7505563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 3303006 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic amniocentesis
Number of subjects: 2264
Study 3303006 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-risk women offered amniocentesis)
Number of subjects: 2264
Study 28365809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensodyne® Rapid Relief (occluding toothpaste)
Number of subjects: 19
Study 28365809 — intervention group
Group type: COMPARATOR
Intervention: Crest® Decay Prevention (non-occluding toothpaste)
Number of subjects: 19
Study 26837214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid training (MHFA)
Number of subjects: 0
Study 26837214 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 0
Study 25609176 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injections (n = 16)
Number of subjects: 32
Study 25609176 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 16)
Number of subjects: 32
Study 23376898 — intervention group
Group type: EXPERIMENTAL
Intervention: New topographic indices computed from digitized images of the Placido rings
Number of subjects: 124
Study 23376898 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal eyes)
Number of subjects: 124
Study 23376898 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus group (KC)
Number of subjects: 124
Study 23376898 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus suspect group
Number of subjects: 124
Study 20712153 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Google Earth as an educational tool in a history of psychology class
Number of subjects: 0
Study 18833862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminous oxide abrasion (27 microm, 40 psi)
Number of subjects: 4
Study 18833862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminous oxide abrasion (50 microm, 40 psi)
Number of subjects: 4
Study 18833862 — intervention group
Group type: COMPARATOR
Intervention: Hand instrument (excavator)
Number of subjects: 4
Study 16632411 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural dietary sources of TFA (milk fat enriched in TFA, approximately 20 g/100 g of total fatty acids)
Number of subjects: 46
Study 16632411 — intervention group
Group type: COMPARATOR
Intervention: Industrial dietary sources of TFA (partially hydrogenated vegetable oils, PHVO)
Number of subjects: 46
Study 14658948 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 64
Study 14658948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10811665 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based systemic and intrathecal chemotherapy + CNS irradiation (for 36 patients)
Number of subjects: 49
Study 10811665 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS disease (CSF+/Mass)
Number of subjects: 49
Study 10811665 — intervention group
Group type: EXPERIMENTAL
Intervention: M2 or M3 marrow status
Number of subjects: 49
Study 10811665 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH levels greater than 500 IU/L
Number of subjects: 49
Study 10811665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CNPs
Number of subjects: 49
Study 8831651 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 138
Study 8831651 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 138
Study 1482143 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of fleroxacin alone
Number of subjects: 20
Study 1482143 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of fleroxacin with 1 g of sucralfate every 6 h starting 24 h before and continuing for 48 h after fleroxacin treatment
Number of subjects: 20
Study 4067973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 155
Study 4067973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 155
Study 4067973 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 155
Study 4067973 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral myringotomy and grommet insertion
Number of subjects: 155
Study 31536984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell exercise (6-pound dumbbells on non-dialysis days for 3 months)
Number of subjects: 86
Study 31536984 — intervention group
Group type: COMPARATOR
Intervention: Control group (squeezed rubber balls)
Number of subjects: 86
Study 30766716 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 395
Study 30766716 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (NET‐EN)
Number of subjects: 395
Study 30766716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 395
Study 30766716 — intervention group
Group type: COMPARATOR
Intervention: Nonuser controls
Number of subjects: 395
Study 30766716 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 395
Study 30766716 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH) level >/= 25.8 mIU/mL
Number of subjects: 395
Study 30766716 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between FSH and BMI
Number of subjects: 395
Study 27539113 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlantic diet (AD group)
Number of subjects: 715
Study 27539113 — intervention group
Group type: COMPARATOR
Intervention: Control diet (C group)
Number of subjects: 715
Study 24803033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate 1 g, 2 g, or 4 g daily
Number of subjects: 166
Study 24803033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 22030709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=13)
Number of subjects: 38
Study 22030709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy (CBT) (n=13)
Number of subjects: 38
Study 22030709 — intervention group
Group type: COMPARATOR
Intervention: Matched-healthy controls (n=36)
Number of subjects: 38
Study 20215520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib therapy
Number of subjects: 33
Study 20215520 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CAF levels
Number of subjects: 33
Study 20215520 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CAF signature (hepatocyte growth factor and IL-12)
Number of subjects: 33
Study 19033112 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCRT at the total dose of 66 to 70 Gy in 33 to 35 fractions
Number of subjects: 68
Study 19033112 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiotherapy (SRT) at the dose of 20 Gy in 4 fractions after 60 Gy 3DCRT
Number of subjects: 68
Study 15820236 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 23
Study 15820236 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 23
Study 12839580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreens with varying ultraviolet A protective capability
Number of subjects: 0
Study 12839580 — intervention group
Group type: COMPARATOR
Intervention: Sunscreens with constant ultraviolet B protection
Number of subjects: 0
Study 10372727 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 14
Study 10372727 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg DHEA
Number of subjects: 14
Study 10372727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8559537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystopexy alone
Number of subjects: 102
Study 8559537 — intervention group
Group type: COMPARATOR
Intervention: Cystopexy with posterior pubourethral ligaments plication
Number of subjects: 102
Study 1866674 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperitonealization of the lesser curve (45 patients)
Number of subjects: 96
Study 1866674 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 96
Study 7065351 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage through a standard Penrose or Chaffin‐Pratt sump tube
Number of subjects: 300
Study 7065351 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 300
Study 31503307 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, 25 mg weekly (n=107)
Number of subjects: 216
Study 31503307 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil, 3 g daily (n=109)
Number of subjects: 216
Study 28285187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 52
Study 28285187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25885521 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx 100 mg
Number of subjects: 51
Study 25885521 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx 200 mg
Number of subjects: 51
Study 25885521 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx 400 mg
Number of subjects: 51
Study 25885521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25885521 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx (all doses)
Number of subjects: 51
Study 25885521 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx
Number of subjects: 51
Study 23539083 — intervention group
Group type: COMPARATOR
Intervention: Aero helmet (AERO)
Number of subjects: 10
Study 21386067 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 175
Study 21386067 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study 19744007 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble tocofersolan (1200 IU for adults, 100 IU/kg for children)
Number of subjects: 24
Study 19744007 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble tocofersolan (100 IU/kg)
Number of subjects: 24
Study 19744007 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study 17184645 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose aspirin (325 mg)
Number of subjects: 63
Study 17184645 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg)
Number of subjects: 63
Study 15100522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate tablets
Number of subjects: 97
Study 15100522 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol solution
Number of subjects: 97
Study 15235337 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure (CRP)
Number of subjects: 9
Study 10090295 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 557
Study 10090295 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 557
Study 7480125 — intervention group
Group type: COMPARATOR
Intervention: Without SAFOs
Number of subjects: 39
Study 7480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Right SAFO
Number of subjects: 39
Study 7480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Left SAFO
Number of subjects: 39
Study 7480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral SAFOs
Number of subjects: 39
Study 2123632 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (Marogen Sterile Powder, Chugai‐Upjohn, Inc.) for an average of 18 months
Number of subjects: 187
Study 2123632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epoetin beta therapy)
Number of subjects: 187
Study 7192884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 9 mEq/d
Number of subjects: 50
Study 7192884 — intervention group
Group type: COMPARATOR
Intervention: Control (no sodium bicarbonate)
Number of subjects: 50
Study 31999500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bauhinia forficata Link tincture (BFLT) 23.2 mg/mL
Number of subjects: 60
Study 31999500 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12%
Number of subjects: 60
Study 31999500 — intervention group
Group type: COMPARATOR
Intervention: Growth control
Number of subjects: 60
Study 31999500 — intervention group
Group type: COMPARATOR
Intervention: Baseline (48h maturation biofilm)
Number of subjects: 60
Study 31999500 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 81.20 g/mL
Number of subjects: 60
Study 31999500 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 60
Study 30643228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous endotoxin
Number of subjects: 115
Study 30643228 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline activity of transcription factors (TFs) related to inflammation (NF-kB) and sympathetic activation (CREB)
Number of subjects: 115
Study 30643228 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline activity of glucocorticoid receptor (GR) related TFs
Number of subjects: 115
Study 27592635 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy targeting intolerance of uncertainty (CBT‐IU)
Number of subjects: 63
Study 27592635 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 63
Study 25515279 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band surgery
Number of subjects: 57
Study 25515279 — intervention group
Group type: COMPARATOR
Intervention: Conservatively treated (dietician and very low calorie diet)
Number of subjects: 57
Study 25515279 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (both interventions)
Number of subjects: 57
Study 24699237 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month internet-delivered physical activity behavioral intervention
Number of subjects: 82
Study 22971184 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece IOL implantation in CACG group
Number of subjects: 93
Study 22971184 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece IOL implantation in CACG group
Number of subjects: 93
Study 22971184 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece IOL group using SRK/T formula
Number of subjects: 93
Study 19943398 — intervention group
Group type: EXPERIMENTAL
Intervention: Working on 2 character strengths
Number of subjects: 76
Study 19943398 — intervention group
Group type: EXPERIMENTAL
Intervention: Working on 1 character strength and 1 relative weakness
Number of subjects: 76
Study 19943398 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 76
Study 17690310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicraniectomy (surgical intervention)
Number of subjects: 32
Study 17690310 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (control)
Number of subjects: 32
Study 15352909 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin estimation
Number of subjects: 73
Study 15352909 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte sedimentation rate > 10 mm
Number of subjects: 73
Study 15352909 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein > 6 mg/L
Number of subjects: 73
Study 15352909 — intervention group
Group type: COMPARATOR
Intervention: Combination of erythrocyte sedimentation rate and C-reactive protein
Number of subjects: 73
Study 12452386 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (12.5% alcohol)
Number of subjects: 10
Study 12452386 — intervention group
Group type: COMPARATOR
Intervention: Juice (matched control)
Number of subjects: 10
Study 9878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 10948
Study 9878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tirofiban and heparin
Number of subjects: 10948
Study 9878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lamifiban
Number of subjects: 10948
Study 9878986 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lamifiban
Number of subjects: 10948
Study 9878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 10948
Study 9005131 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (Group A)
Number of subjects: 46
Study 9005131 — intervention group
Group type: COMPARATOR
Intervention: Peridural anaesthesia (Group B)
Number of subjects: 46
Study 30782765 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed shared decision-making programme
Number of subjects: 0
Study 30782765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28984076 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Behavioral Treatment (FBT)
Number of subjects: 241
Study 26316194 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet CBT adjunctive to specialized headache treatment
Number of subjects: 83
Study 26316194 — intervention group
Group type: COMPARATOR
Intervention: Specialized headache treatment alone
Number of subjects: 83
Study 26316194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Internet CBT and control)
Number of subjects: 83
Study 23746673 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate total provisional prosthesis on temporary immediate implants (test group, 12 patients)
Number of subjects: 16
Study 23746673 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 patients)
Number of subjects: 16
Study 20213220 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-based combinations
Number of subjects: 0
Study 20213220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-based combinations
Number of subjects: 0
Study 20213220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based combinations
Number of subjects: 0
Study 20213220 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational agents
Number of subjects: 0
Study 17217360 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (24-page booklet, 30-minute audio-CD, and worksheet) in addition to usual care
Number of subjects: 0
Study 17217360 — intervention group
Group type: COMPARATOR
Intervention: Usual care only with standard counselling
Number of subjects: 0
Study 16373258 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (30 mg/20 mg daily for <45/≥46 years)
Number of subjects: 41
Study 16373258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16373258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during active treatment
Number of subjects: 41
Study 12027839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0% with 5 microg/kg/h remifentanil)
Number of subjects: 20
Study 12027839 — intervention group
Group type: COMPARATOR
Intervention: Propofol (3 mg/kg/h with 5 microg/kg/h remifentanil)
Number of subjects: 20
Study 12027839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 10204127 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg i.v. single dose)
Number of subjects: 272
Study 10204127 — intervention group
Group type: COMPARATOR
Intervention: Cephradine (1 g i.v. + metronidazole (1 g rectally) with two further doses of cephradine and metronidazole
Number of subjects: 272
Study 10204127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 272
Study 7774110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.7 gm eicosapentaenoic acid and 1.1 gm docosahexaenoic acid/day)
Number of subjects: 45
Study 7774110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2338403 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (170 mg/kg for acute treatment)
Number of subjects: 0
Study 2338403 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (140 mg/kg/day for chronic treatment)
Number of subjects: 0
Study 2338403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7437777 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial reconstruction
Number of subjects: 26
Study 7437777 — intervention group
Group type: COMPARATOR
Intervention: Unilateral nephrectomy
Number of subjects: 26
Study 31676314 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake craniotomy (AC)
Number of subjects: 246
Study 31676314 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy under general anesthesia (GA)
Number of subjects: 246
Study 30088321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review and patient interview upon admission (intervention ED)
Number of subjects: 600
Study 30088321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review and patient interview upon admission, medication review during inpatient stay, and medication report and patient counselling at discharge (intervention STAY)
Number of subjects: 600
Study 30088321 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 600